<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="171562">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00862979</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001ADE14</org_study_id>
    <secondary_id>2007-002671-14</secondary_id>
    <nct_id>NCT00862979</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients</brief_title>
  <acronym>MANDELA</acronym>
  <official_title>A 15-month, Multi-center, Randomized, Open-label, Parallel Group Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Regimen (Everolimus and Mycophenolic Acid) Versus a Standard Regimen (Cyclosporine A and Everolimus) in de Novo Heart Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess whether a calcineurin inhibitor (CNI)-free regimen with everolimus
      and mycophenolic acid is associated with a better renal outcome as compared to the standard
      regimen containing cyclosporine A (which belongs to the class of CNIs) and everolimus; while
      both treatments are expected to be comparable with respect to efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess whether a calcineurin inhibitor (CNI)-free regimen with everolimus
      and mycophenolic acid is associated with a better renal outcome as compared to the standard
      regimen containing cyclosporine A (which belongs to the class of CNIs) and everolimus; while
      both treatments are expected to be comparable with respect to efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function assessed as glomerular filtration rate (GFR) - MDRD formula</measure>
    <time_frame>18 months after heart transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of treatment failures</measure>
    <time_frame>up to or at Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of major cardiac events and each of its components</measure>
    <time_frame>Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function by GFR - Cockcroft-Gault method</measure>
    <time_frame>Month 12 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal function and evolution of renal function (creatinine slope)</measure>
    <time_frame>between Month 6 and Month 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>Month 6, 9 and 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Heart Transplantation</condition>
  <arm_group>
    <arm_group_label>Certican CNI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MMF OR Myfortic, Certican®, Sandimmun® optoral reduced</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Certican</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MMF or Myfortic+ Everolimus + corticosteroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sandimmun Optoral / Tac + RAD001</intervention_name>
    <description>RAD001 / CNI group</description>
    <arm_group_label>Certican CNI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MPA + RAD001</intervention_name>
    <description>RAD001 / MPA group</description>
    <arm_group_label>Certican</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Heart transplantation, 3 months prior to enrollment

          -  Patients have to receive an immunosuppressive regimen with Sandimmun® Optoral,
             Certican® and corticosteroids

          -  Sufficient graft function

          -  Sufficient renal function

          -  Females capable of becoming pregnant must have a negative serum pregnancy test within
             7 days prior to or at baseline, and are required to practice an approved method of
             birth control for the duration of the study and for a period of 6 weeks following
             discontinuation of study medication, even where there has been a history of
             infertility

        Exclusion criteria:

          -  Multi-organ recipients, re-transplantation, or previous transplant with any other
             organ.

          -  Patients who are recipients of A-B-O incompatible transplants

          -  Cold ischemia time &gt;6 hours

          -  Historical or current peak PRA of &gt; 25% at time of transplantation

          -  Already existing antibodies against the HLA-type of the receiving transplant Other
             protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 2, 2016</lastchanged_date>
  <firstreceived_date>March 16, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Transplantation</keyword>
  <keyword>Cardiac Transplantation</keyword>
  <keyword>CNI-sparing</keyword>
  <keyword>renal function</keyword>
  <keyword>CNI</keyword>
  <keyword>Cyclosporine A</keyword>
  <keyword>Everolimus</keyword>
  <keyword>enteric coated mycophenolic acid</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
